European journal of cancer (Oxford, England : 1990)HumansFemalePancreatic NeoplasmsMiddle AgedMale
Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment.
Mélanie Debiais, Anthony Tarabay, Sarah Blanchet-Deverly, Géraldine M Camilleri, Alexandre Megherbi, Laura Diebakate, Maxime Collin, Antoine Hollebecque, Cristina Smolenschi, Marine Valéry, Thomas Pudlarz, Alina Cristina Fuerea, Valérie Boige, Michel Ducreux, Alice Boilève
Published: 202610.1016/j.ejca.2025.116160
Abstract
BACKGROUND: Metastatic pancreatic adenocarcinoma (mPDAC) has a poor prognosis. FOLFIRINOX (FFX) and gemcitabine nab-paclitaxel (GN) are the preferred first line (L1) regimens. We evaluated real-world outcomes of L1 therapies. METHODS: Retrospective a…
Preview only. Read the full abstract at the source